PharmacoEconomics & Outcomes News 784, p34 - 12 Aug 2017 NICE gives final approval for IBS drug eluxadoline NICE has approved the drug, eluxadoline [Truberzi; Allergan] for routine funding on the NHS to treat patients with irritable bowel syndrome and diarrhoea (IBS-D) who have not responded to, or are cannot take other treatments. Truberzi will be available alongside existing drug and psychological treatments for IBS-D, including drugs that stop spasms in the gut or hypnotherapy. NICE has recommended that Truberzi only be offered in secondary care providing it is stopped after 4 weeks if the treatment is not working. "IBS-D can significantly impact a person’s quality of life, sometimes leading to anxiety and affecting their daily activities. The committee heard that having this treatment available when others no longer work will be welcomed by patients", said Director of the Centre for Health Technology Evaluation at NICE, Professor Carole Longson. NICE. GBP3 a day drug for irritable bowel syndrome gets NICE approval. Media Release : 27 Jul 2017. Available from: URL: http://www.nice.org.uk 809220392 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784
PharmacoEconomics & Outcomes News – Springer Journals
Published: Aug 12, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera